Urology Times staff

 discusses the unmet need for a preventive treatment for patients with recurrent urinary tract infections (UTIs). At the 2021 AUA Annual Meeting, Nickel shared results from the groundbreaking study, "“

A novel sublingual vaccine will dramatically alter the clinical management of recurrent urinary tract infections in women

Nickel is a professor of the department of urology at Queen’s University and urologist at Kingston and Hotel Dieu General Hospitals, Kingston, Ontario, Canada.

Videos

“We have the rising spectra of national and international antibiotic resistance, which is becoming a huge international medical issue,” says J. Curtis Nickel, MD.

Novel MV140 vaccine is “game changing” for recurrent UTIs

® Assistant Editor Janelle Hart spoke with 

 He discusses how his new technology, The PrecisionPoint Transperineal Access System, is used for detecting prostate cancer in patients. Matthew J. Allaway, MD, is the founder and president of Perinealogic and a urologist and managing partner at Urology Associates, Cumberland, Maryland.

Podcasts

“We need to do a better job sampling the prostate,” says Matthew J. Allaway, MD.

Dr. Allaway on the increased efficiency of transperineal biopsies

discusses the background and findings of the study, “MRI-guided focused ultrasound (MRgFUS) focal therapy for intermediate-risk prostate cancer: final results of a phase IIb multicenter study,” 

presented at the 2021 American Urological Association annual meeting

. Ehdaie is an assistant member of the urology service department of surgery at Memorial Sloan Kettering Cancer Center, New York City, New York

“Although [whole-gland] treatments are very successful, from the oncologic perspective, our goal was to develop and test a new treatment modality in which we treat only the area with the significant cancer using focused ultrasound in the MRI gantry,” says Behfar Ehdaie, MD, MPH.

Study finds focal therapy a safe option for treating intermediate-risk prostate cancer

In this video, Kelly L. Stratton, MD, discusses further research on the study, “Novel weekly immunotherapy dosing with avelumab tolerated during Bacillus Calmette-Guerin induction therapy: Initial results of the ABD trial,” 

presented at the 2021 American Urological Association Annual Meeting

, and his take on the current state of BCG-unresponsive non–muscle-invasive bladder cancer. Stratton is an assistant professor of urologic oncology at the University of Oklahoma, Oklahoma City.

“BCG-unresponsive non–muscle-invasive bladder cancer is really [an] evolving space with a lot of uncertainty,” says Kelly L. Stratton, MD.

Urology Times staff

Articles

Novel MV140 vaccine is “game changing” for recurrent UTIs

Dr. Allaway on the increased efficiency of transperineal biopsies

Study finds focal therapy a safe option for treating intermediate-risk prostate cancer

Dr. Stratton discusses combo of avelumab and BCG in NMIBC